Palladian Health names new chairman
Mr Donahue succeeds Palladian founder Kevin Cichocki, who was elected vice chairman of the board and will continue to serve as chief clinical officer. Paul Candino was also
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).